Dioxetane-based chemiluminescence probes, more specifically fluorophore-tethered dioxetane-based chemiluminescence probes and * acceptor group-containing dioxetane based chemiluminescence probes can be included in compositions. The chemiluminescence probes are useful for both diagnostics and in vivo imaging.

The present invention is directed, in certain embodiments, to polymerizable near-IR dyes and polymers comprising said dyes as monomeric residues. In other embodiments, the present invention also relates to methods for the preparation of polymerizable near-IR dyes, and to the use of polymerizable near-IR dyes in the preparation of fluorescent polymers.

A method of quenching excited state energy from a photodegradable pigment that has been excited by absorption of light having a wavelength in the wavelength range of 290-800 nm, comprising reacting a pigment with a conjugated fused tricyclic compound having electron withdrawing groups of Formula (II) or a salt thereof: ##STR00001## wherein: A is selected from the group consisting of O, S, CO, CS, ##STR00002## B.sup.1, B.sup.2, D.sup.1 and D.sup.2 are each independently selected from the group consisting of F, Cl, Br, I, CF.sub.3, CC13, NR33+, NO2, CN, C(O)R4, C(O)OR, SO2R5, aryl, and CCHR6; each m independently is 0, 1, 2, 3, or 4; a is 0 or 1; each R is independently selected from the group consisting of LI, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl; R.sup.2 is selected from the group consisting of H, alkyl, cycloalkyl, alkenyl, alkynyl, and aryl; each R.sup.3 is independently selected from the group consisting of H and C.sub.1-C.sub.6 alkyl; each R.sup.4 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl; each R.sup.5 is independently selected from the group consisting of H, O, OH, NH.sub.2, and Cl; and each R.sup.6 is-independently selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and aryl.

The application provides fluorescent dyes, which are cyanine dyes that incorporate additional aza moieties in the indolenium heterocycles and/or in the methine chains connecting them. Symmetrical and unsymmetrical chemically reactive azacyanine dyes are described for conjugation, as well as their bioconjugates for in-vitro and in-vivo assays and fluorescence imaging.

An embodiment of the present invention is to provide a resin composition including a near infrared absorbing coloring agent represented by Formula (1) and a resin, a resin molded article, and a method of producing a resin molded article. In Formula (1), a ring A and a ring B each independently represent an aromatic ring or a heteroaromatic ring, X.sup.A and X.sup.B each independently represent a monovalent substituent, G.sup.A and G.sup.B each independently represent a monovalent substituent, kA represents an integer of 0 to n.sub.A, kB represents an integer of 0 to n.sub.B, n.sub.A represents the largest integer of G.sup.A which may be substituted in the ring A, n.sub.B represents the largest integer of G.sup.B which may be substituted in the ring B, X.sup.A and G.sup.A, and X.sup.B and G.sup.B may be respectively bonded to one another to form a ring, and in a case where a plurality of G.sup.A's and G.sup.B's are present, the plurality of G.sup.A's and the plurality of G.sup.B's may be respectively bonded to one another to form a ring structure.

##STR00001##

A film in which a light transmittance when light is transmitted from one surface of the film to the other surface has a maximum value of 10% or lower in a wavelength range of 400 to 830 nm and has a minimum value of 70% or higher in a wavelength range of 1000 to 1300 nm.

Disclosed is a pentamethine cyanine dye of formula (I) and a method of producing the same, where the dye is suitable as a fluorescent material for the STORM and SOFI super-resolution imaging.

A method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate or 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle.

The present invention generally relates to sensitizer compounds and their use in combination with Tyrosine Kinase Inhibitors (TKIs) for sensitizing tumor, cancer or pre-cancerous cells to TKI treatment. In particular, the present invention relates to administration regimes that combine TKIs such as Gefitinib or Icotinib with TKI-sensitizing DZ1 esters and amides conjugated to statin or platin-based drugs, or to Artemisinin, including, without limitation: DZ1-Simvastatin amide, DZ1-Simvastatin ester, DZ1-Cisplatin ester, and DZ1-Cisplatin amide, DZ1-Artemisinin ester, and DZ1-Artemisinin amide. Furthermore, the present invention relates to improved TKI treatment of cancers by sensitizing tumor, cancer or pre-cancerous cells, in particular cancers that develop TKI resistance, including e.g. lung cancer and pancreatic cancer.

A composition comprising: a polymorphic form of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-ulfonatobutyl)-3H-indol- 1- ium-5-sulfonate or 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate and an acceptable excipient.